BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23985912)

  • 1. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
    Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
    J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
    Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
    J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
    Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.
    Saville M; Sultana F; Malloy MJ; Velentzis LS; Caruana M; Ip ELO; Keung MHT; Canfell K; Brotherton JML; Hawkes D
    J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30463896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
    BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
    Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
    J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
    Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
    J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
    Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
    J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
    Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
    Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.
    Reid JL; Wright TC; Stoler MH; Cuzick J; Castle PE; Dockter J; Getman D; Giachetti C
    Am J Clin Pathol; 2015 Sep; 144(3):473-83. PubMed ID: 26276778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
    Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
    J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
    Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
    Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
    Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
    Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
    Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
    J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
    Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
    BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.